Polymorph screening is the identification and characterisation of all relevant polymorphic forms of a pharmaceutical compound. Many pharmaceutical compounds are able to form two or more crystalline phases, this is known as polymorphism. It is important that the polymorphs of a compound are assessed, as different polymorphs have different physicochemical properties that may have an impact on the intended use of the material. The selection of a specific crystal form of an API early in drug discovery mitigate the chances of risk in the later stages of development.
- Reduced risk of failure during development
- Meeting regulatory requirements
- Strengthened intellectual property
